Orestis Lazos

Associate Director

Orestis has more than 9 years’ consultancy experience.

He has worked on a wide range of projects, including value proposition development and testing, payer communication materials, HTA and systematic literature reviews, gap analyses, primary and secondary research, and other strategic P&R projects for indications including cardiovascular disease, oncology, immunology, and allergy.

Orestis is also involved in digital platform development and has experience in digital therapeutics.

He has 7 years’ experience in biochemical research and holds a PhD in Biochemistry from the University of Cambridge.

The insights you need to get the inside edge

Driving BioPharma Access in Europe: Insights for Markets Outside of EU5  

Welcoming Lewis Ruff, Senior Director, Global HEOR, within our policy, access, value, and evidence capability

Adapting to Change: Strategies for Pharma Service Providers, CROs, and R&D Partnerships in the Era of the Inflation Reduction Act

Forecasting global value assessments for a rare-disease drug

Welcoming Tyler Piazza, Partnerships Director, HEOR and hēRo3, within our policy, access, value, and evidence capability

Welcoming Caroline Solon, Senior Director Global Market Access, within our policy, access, value, and evidence capability

Cross-functional integrated evidence generation planning for a therapy treating ANCA‑associated vasculitis (AAV)

Digital therapeutics: policy, access, value, and evidence

The hēRo3 Revolution: Accelerating and Empowering HEOR Analytics with Cutting-Edge Digital Solutions

Value, Evidence, and Access: insights for markets outside of the EU5